Press release
EverFriends.ai Revolutionizes Dementia Treatment with Digital Companionship for Elderly
Daniel Hungerford and the rest of the team at EverFriends.ai are leaving no stone unturned in the pursuit of using technology to provide social isolation solutions for seniors and persons suffering from dementia and loneliness. In a related development, the company recently announced plans to launch a mobile app on iOS and Android.
Recent stats released by the World Health Organization (WHO) reveal that more than 55 million people globally live with dementia, with the number expected to almost double every two decades. Over the years, experts across different fields have created possible solutions to help people with this condition deal with it. However, more must be done, especially in making empathy and companionship easily accessible. Therefore, the recent strides by the EverFriends.ai [https://everfriends.ai/] team are worth every accolade coming the company's way.
EverFriends.ai has announced plans to officially launch its app on IOS and Android in December, a move that reiterates the company's commitment to bringing support to as many people as possible in different parts of the world. The easy-to-navigate mobile app has a user-friendly interface, with amazing features, such as personalized reminders, realistic digital humans, and emergency SOS. Users of the app also enjoy 24x7 Premium Support, access to engaging discussions with conversational AI for seniors [https://everfriends.ai/], real-time connection with friends and family, as well as cognitive stimulation, providing all-inclusive support to people with dementia and bringing quality living within their reach.
The transformational app is one of the several solutions planned from EverFriends.ai to deliver cognitive support for the elderly and help millions of people leverage AI for loneliness in aging adults.
To learn more about the mobile app and other elderly care technology from EverFriends.ai, visit - https://everfriends.ai/. EverFriends.ai also has a growing online community across social media, including Facebook [https://www.facebook.com/everfriendsai/] and YouTube [https://www.youtube.com/@everfriendsai].
About EverFriends.ai
EverFriends.ai was founded primarily to use technology to deliver care to persons with dementia and loneliness. The company offers a revolutionary technology designed to bring comfort, meaningful conversations, and emotional support within the reach of people with this condition and ultimately enhance their quality of life.
Media Contact
Company Name: Everfriends.ai
Contact Person: Daniel Hungerford
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=everfriendsai-revolutionizes-dementia-treatment-with-digital-companionship-for-elderly]
Phone: 616-8221737
Country: United States
Website: http://everfriends.ai
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release EverFriends.ai Revolutionizes Dementia Treatment with Digital Companionship for Elderly here
News-ID: 3714711 • Views: …
More Releases from ABNewswire
Ophthalmoscopes Market to Reach USD 294.90 Million by 2034, Growing at 5.24% CAG …
Leading ophthalmoscopes companies in the market include Baxter, HEINE Optotechnik GmbH & CO. KG, Keeler, US Ophthalmic, Rudolf Riester GmbH, Opticlar, Zumax Medical Co., Ltd., Girodmedical, Adam Rouilly Ltd., Timesco Healthcare Ltd., Zhejiang Honsun Medical Technology Co., Ltd., Iridex Corporation, NIDEK CO., Ltd., OSCAR BOSCAROL S.r.l, American Diagnostic Corporation, Lumenis Be Ltd., Veatch Ophthalmic Instruments, KIRCHNER &WILHELM GmbH + Co. KG, oDocs Eye care, Revenio Group, and others.
The global ophthalmoscopes…
RINVOQ Market Growth Accelerates Across IBD, Dermatology, and Rheumatology as Gl …
The global immunology market is witnessing a significant transformation as RINVOQ (upadacitinib) continues to demonstrate strong prescription growth, expanding indications, and robust revenue performance.
DelveInsight's "RINVOQ Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of RINVOQ for approved indications like Ankylosing Spondylitis, Atopic Dermatitis, Axial SpA, Crohn's Disease, Giant Cell Arteritis, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis; as well as potential indications like Alopecia Areata, Hidradenitis…
Prostate Cancer Competitive Landscape Analysis 2026: Clinical Trial Trends, Nove …
Leading Prostate Cancer companies include Merck & Co., Inc., Telix Pharmaceuticals Limited, Exelixis, Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, AbbVie Inc., BeiGene, Ltd., and Ipsen S.A., among many others-are actively developing next-generation therapies to reshape the treatment landscape.
The treatment paradigm for prostate cancer is witnessing rapid transformation, with more than 150 companies advancing innovative drug candidates across diverse clinical phases. Recent milestones include multiple FDA fast-track designations, companion…
Electrosurgical Devices Market to Reach USD 10,220.04 Million by 2034, Growing a …
Electrosurgical Devices Companies in the market include B. Braun Melsungen AG, ConMed Corporation, Olympus Corporation, Apyx Medical Corporation, Medtronic, Johnson & Johnson, Smith & Nephew Plc, Erbe Elektromedizin GmbH, KLS Martin Group, BOWA-electronic GmbH & Co. KG, Modern Medical, Kirwan Surgical Products, LLC, Utah Medical Products, Inc., Hangzhou AGS MedTech Co., Ltd., New Deantronics Taiwan Ltd., Parkell, Inc., Surgical Holdings, CIMPAX, Boston Scientific Corporation, and Others
The global electrosurgical devices market…
